-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
-
Quebec's incoming separatist leader wants to block Crown from swearing-in
-
As Messi bows out, Argentines say 'thank you'
-
Emmys gala will now stream its premier television awards
-
Ronaldo opens door for Portugal return, apologises for walkout
-
Paramount completes Warner Bros takeover, creating Skydance
-
'Nobody seems to care': Russian city shrugs off plague reports
-
Trump blames France unrest on Islam, migration
Trump administration does about face on autism treatment
The Trump administration did an about-face Tuesday on an autism treatment it had promoted with great fanfare.
It had said back in September it would approve use of a drug called leucovorin -- synthetic vitamin B9 -- to treat the disorder.
But on Tuesday the Food and Drug Administration backed off, citing insufficient evidence that it works for the condition.
The initial announcement came from Health Secretary Robert F. Kennedy Jr, who for decades has spread debunked claims that vaccines cause autism.
Kennedy touted leucovorin, usually used to alleviate chemotherapy side effects, as an "exciting therapy" that could help children with autism, a disorder whose symptoms vary widely across a spectrum.
"This gives hope to the many parents with autistic children that it may be possible to improve their lives," President Donald Trump said in September at a press conference.
At the event he gave sweeping, unsubstantiated advice on autism, such as insisting that pregnant women should "tough it out" and avoid Tylenol over an unproven link to autism -- statements slammed by scientists.
Studies on a small number of patients have suggested that taking leucovorin can help ease some communication or personal-relations problems linked to autism, but experts say this issue needs more study.
On Tuesday the FDA said it was in fact approving use of leucovorin for a rare condition called cerebral folate deficiency but not for autism.
The Trump administration's touting of it for autism ran the risk of raising false hopes, dozens of autism specialists said at the time in a joint letter.
"We don't have sufficient data to say that we could establish efficacy for autism more broadly," an FDA official told NBC News.
"It'll be up to patients to talk with their physicians to see if that might be right for them," said the official, whose name was not given.
A.AbuSaada--SF-PST